Drug’s antiinflammatory properties may help alleviate pain in patients with OA, reduce risk of myocardial infarction, but toxicity, drug interactions need to be considered
Search results for: cardiovascular
Statin Guideline Eliminates Cholesterol Treat-to-Target Strategy for Managing Atherosclerotic Cardiovascular Risk
Experts question how to apply the new American College of Cardiology and American Heart Association guidelines in patients with rheumatic disease and call for further validation of the risk assessment algorithm
Does Anti-Tumor Necrosis Factor-Alpha Increase Cardiovascular Burden?
Long-term use of TNFα inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis is associated with both gains in fat mass and a shift in fat mass to the visceral region. (posted Jan. 14)
Researcher Studies Ways to Cut Cardiovascular Disease Risk in Rheumatoid Arthritis Patients
Better communication and more proactive partnerships between rheumatologists and primary care physicians may help modify CVD risk factors for patients with rheumatoid arthritis
Foundation Research Explores Relationship Between RA and Cardiovascular Disease
A grant from the Rheumatology Research Foundation has set two physicians on a course to examine how high-density lipoprotein (HDL) cholesterol is different in rheumatoid arthritis patients
Cardiovascular Disease in Rheumatoid Arthritis
How to improve management of heart disease in patients with RA.
Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk
Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.
Cardiovascular Disease Risk High in RA Patients
High incidence of metabolic disease and concurrent inflammation increases risk
3 AC&R Study Summaries: Frailty & Prefrailty in RA, Premature Mortality in Gout & Using Recruitment & Multidisciplinary Care Incentives to Improve Access
Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…
Reflecting on B Cell-Depleting Therapies & COVID-19
In the early days of the COVID-19 pandemic, confusion and concern for immunosuppressed patients grew among rheumatologists and patients alike. Research has helped bridge the knowledge gap, and treatment options for COVID-19 have helped ease concerns.
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 65
- Next Page »